Article
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.
Med (New York, N.Y.) - 10 May 2024
Zeng Liang, Song Lianxi, Liu Li, Wu Fang, Xu Qinqin, Yan Huan, Lin Shaoding, Jiang Wenjuan, Wang Zhan, Deng Li, Qin Haoyue, Zhang Xing, Xiao Jiwen, Liu Min, Liu Zhaoyi, Zhang Lin, Zhou Chunhua, Xiong Yi, Wang Ya, Zhang Yongchang, Yang Nong
Abstract excerpt
BACKGROUND: BEBT-109 is an oral pan-mutant-selective inhibitor of epidermal growth factor receptor (EGFR) that demonstrated promising antitumor potency in preclinical models. METHODS: This first-in-human study was a single-arm, open-label, two-stage study. Phase Ia dose-escalation study evaluated the safety and pharmacokinetics of BEBT-109 in 11 patients with EGFR T790M-mutated advanced non-small cell lung cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.